Want to see AU:ACW full AI Analyst Report?

Actinogen Medical (ACW) Price & Analysis

43 Followers

ACW Stock Chart & Stats

AU$0.04

>-AU$0.01(-2.33%)

At close: Jul 27 4:00 PM EDT

AU$0.04

>-AU$0.01(-2.33%)

Day’s Range― - ―

52-Week RangeAU$0.03 - AU$0.07

Previous CloseN/A

Volume826.35K

Average Volume (3M)1.86M

Market Cap

AU$180.04M

Enterprise ValueAU$90.43

Total Cash (Recent Filing)AU$16.73M

Total Debt (Recent Filing)AU$4.78M

Price to Earnings (P/E)―

Beta-0.02

Next Earnings

Feb 24, 2027

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)>-0.01

Shares Outstanding3,750,803,000

10 Day Avg. Volume1,430,663

30 Day Avg. Volume1,863,025

Financial Highlights & Ratios

PEG Ratio1.10

Price to Book (P/B)4.83

Price to Sales (P/S)0.00

P/FCF Ratio-5.88

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

AU$0.08

Price Target Upside100.00% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)>-0.01

Revenue Forecast (FY)AU$38.50M

Bulls Say, Bears Say

Bulls Say

Focused Drug-development PlatformA focused small-molecule platform and a lead oral candidate provide a defined development strategy. Success in targeted neurological indications could create a scalable product opportunity, although value remains dependent on clinical and regulatory progress.

Positive Equity PositionPositive equity and moderate leverage provide a financial cushion relative to a highly debt-funded structure. This may preserve some flexibility for ongoing development, although continued losses could erode the cushion over time.

Growing Asset BaseAn expanding asset base indicates that the company retains tangible financial resources supporting its development operations. This is a relative strength for a clinical-stage biotechnology business, despite the need to manage ongoing cash consumption.

Bears Say

Revenue Collapsed To ZeroThe disappearance of revenue materially weakens financial quality and demonstrates that the company is not currently supported by a dependable commercial revenue stream. This increases reliance on clinical progress and future external financing.

Persistent Cash BurnDeeply negative operating and free cash flow show that the business is not self-funding. Continued development therefore depends on external capital, creating funding, dilution and execution risks over the next several months.

Widening Losses And Weak ReturnsLarge operating and net losses, combined with strongly negative returns on equity, indicate weak profitability and limited earnings visibility. If losses persist, equity may continue to decline and additional financing could become necessary.

Actinogen Medical News

Actinogen Medical Seeks ASX Quotation for 11.9 Million New Shares

Actinogen Medical ( ($AU:ACW) ) has provided an update. Actinogen Medical has applied to the ASX for quotation...

3d ago

Actinogen Plans Major Share Placement to Bolster Funding Capacity

Actinogen Medical ( ($AU:ACW) ) just unveiled an update. Actinogen Medical Limited, an ASX-listed biotechnology company trading under...

5d ago

Actinogen secures full underwriting of $4.77m options to extend Xanamem funding runway

Actinogen Medical ( ($AU:ACW) ) has issued an announcement. Actinogen Medical has secured full underwriting of its remaining...

5d ago

Actinogen Medical Seeks ASX Quotation for 3.6 Million New Shares

The latest announcement is out from Actinogen Medical ( ($AU:ACW) ). Actinogen Medical Limited has applied for quotation...

9d ago

Actinogen director increases shareholding through option exercise

Actinogen Medical ( ($AU:ACW) ) has provided an announcement. Actinogen Medical has reported a change in director Dr...

9d ago

Actinogen Director Increases Equity Stake Through Option Exercise

Actinogen Medical ( ($AU:ACW) ) has issued an announcement. Actinogen Medical has disclosed a change in interests held...

9d ago

Actinogen Medical Seeks ASX Quotation for 6.9 Million New Shares

Actinogen Medical ( ($AU:ACW) ) has provided an announcement. Actinogen Medical has applied for quotation on the ASX...

9d ago

Actinogen Medical Updates Corporate Governance Framework to Align with ASX Standards

Actinogen Medical ( ($AU:ACW) ) has shared an update. Actinogen Medical has issued an updated Corporate Governance Statement...

10d ago

Actinogen readies pivotal Alzheimer’s data as R&D spend climbs

An announcement from Actinogen Medical ( ($AU:ACW) ) is now available. Actinogen has reported its FY2026 results, highlighting...

10d ago

Actinogen Director Boosts Shareholding Through Option Exercise

Actinogen Medical ( ($AU:ACW) ) just unveiled an announcement. Actinogen Medical has reported a change in director interests...

17d ago

ACW FAQ

What was Actinogen Medical Limited’s price range in the past 12 months?

Actinogen Medical Limited lowest share price was AU$0.03 and its highest was AU$0.07 in the past 12 months.

What is Actinogen Medical Limited’s market cap?

Actinogen Medical Limited’s market cap is AU$180.04M.

When is Actinogen Medical Limited’s upcoming earnings report date?

Actinogen Medical Limited’s upcoming earnings report date is Feb 24, 2027 which is in 172 days.

How were Actinogen Medical Limited’s earnings last quarter?

Actinogen Medical Limited released its earnings results on Aug 27, 2026. The company reported -AU$0.001 earnings per share for the quarter.

Is Actinogen Medical Limited overvalued?

According to Wall Street analysts Actinogen Medical Limited’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Actinogen Medical Limited pay dividends?

Actinogen Medical Limited does not currently pay dividends.

What is Actinogen Medical Limited’s EPS estimate?

Actinogen Medical Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Actinogen Medical Limited have?

Actinogen Medical Limited has 3,750,803,000 shares outstanding.

What happened to Actinogen Medical Limited’s price movement after its last earnings report?

Actinogen Medical Limited reported an EPS of -AU$0.001 in its last earnings report. Following the earnings report the stock price went down -4.545%.

Which hedge fund is a major shareholder of Actinogen Medical Limited?

Currently, no hedge funds are holding shares in AU:ACW

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Actinogen Medical Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

27.64%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Actinogen Medical Limited

Actinogen Medical Limited is an Australian biotechnology company dedicated to developing treatments for neurological and neuropsychiatric disorders linked to imbalanced brain cortisol levels. Their lead product, Xanamem, an inhibitor of the 11ß-HSD1 enzyme, is currently in Phase 2 clinical trials. This compound has demonstrated target engagement within the central nervous system and is being investigated for its potential in conditions such as Alzheimer's disease, depression with cognitive impairment, and the anxiety, sleep, and behavioral issues associated with fragile X syndrome. Founded in 1999, the company was formerly known as Actinogen Limited, adopting its current name in November 2015, and is headquartered in Sydney, Australia.

Actinogen Medical (ACW) Earnings & Revenues

Historic Earnings Reports

ACW Stock 12 Month Forecast

Average Price Target

AU$0.08

▲(100.00% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"AU$0","1":"AU$1","-1":"-AU$1","-0.5":"-AU$0.5","0.5":"AU$0.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":0.08,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">AU$0.08</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.08,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">AU$0.08</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.08,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">AU$0.08</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,-0.5,0,0.5,1],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.041,0.044000000000000004,0.047,0.05,0.053000000000000005,0.056,0.059000000000000004,0.062,0.065,0.068,0.07100000000000001,0.07400000000000001,0.07700000000000001,{"y":0.08,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.041,0.044000000000000004,0.047,0.05,0.053000000000000005,0.056,0.059000000000000004,0.062,0.065,0.068,0.07100000000000001,0.07400000000000001,0.07700000000000001,{"y":0.08,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.041,0.044000000000000004,0.047,0.05,0.053000000000000005,0.056,0.059000000000000004,0.062,0.065,0.068,0.07100000000000001,0.07400000000000001,0.07700000000000001,{"y":0.08,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.028,"date":1756684800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.03,"date":1759276800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.035,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.059,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.061,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.044,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.041,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.037,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.046,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.04,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.032,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.041,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.041,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >